Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Bifurcation Continues; Banks Remain A Concern The bifurcation between large-cap growth and small-caps that we discussed last week has continued, where small-caps have generally not been participating in the rally. As we said last week, this bifurcation can continue, but it is not the type of breadth that supports a sustainable new bull market. We need to see the Russell 2000 (IWM) stay above $209 in order to have confidence that the bottom is in. Meanwhile, stick with the commodity and defensiv...
The independent financial analyst theScreener just lowered the general evaluation of HENRY SCHEIN (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 19, 2021, the closing price was USD 76.9...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Summary Marketline's Align Technology, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Align Technology, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the...
LVS currently trades above corporate averages relative to Uniform earnings, with a 47.4x Uniform P/E (Fwd V/E'). Even at these levels, the market is pricing in expectations for Uniform ROA to decline from 16% in 2019 to 12% in 2024, accompanied by 1% Uniform asset growth going forward. Meanwhile, analysts have similar expectations, projecting Uniform ROA to only rebound to 13% in 2021 after a poor 2020, accompanied by 2% Uniform asset shrinkage. That said, management is confident about Macao rev...
Henry Schein, Inc. (HSIC:USA) currently trades below recent averages relative to UAFRS-based (Uniform) earnings, with a 16.3x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may be concerned about market growth, supply chain issues, and dental service closures in China Specifically, management may be concerned about their entry into the Nordic dental market, and they may lack confidence in their ability to sustain operating margin growth and driv...
• A number of Consumer Cyclical names continue to indicate leadership. (ex. THO, WGO, CROX, WLH, LEN, KBH, PZZA, TXRH, SCVL, GCO, and RH) • The Healthcare Sector has a number of attractive names developing major bases and staging RS reversals. (ex. CAH, HSIC, ITGR, ABT, MLAB, RMD, SYK, MD, RDNT, TRHC, CNC, WCG, RGNX, BEO, and SYNH) • The Technology Sector continues to be long-term leadership. Many issues are extended and we would suggest taking opportunity of any weakness. (ex. TER, AMAT...
Henry Schein's fiscal first-quarter results broadly met our expectations, and we are reiterating our no-moat rating. We anticipate a potential slight increase to our fair value estimate after we incorporate management's minor lift in 2019 outlook. The company raised the top end of its non-GAAP 2019 EPS guidance range by four cents, which now spans $3.38-$3.50 (versus our previous estimate of $3.40). We continue to view 2019 as a transitional year for Henry Schein, as the company works through it...
Henry Schein's fiscal first-quarter results broadly met our expectations, and we are reiterating our no-moat rating. We anticipate a potential slight increase to our fair value estimate after we incorporate management's minor lift in 2019 outlook. The company raised the top end of its non-GAAP 2019 EPS guidance range by four cents, which now spans $3.38-$3.50 (versus our previous estimate of $3.40). We continue to view 2019 as a transitional year for Henry Schein, as the company works through it...
Henry Schein's fiscal first-quarter results broadly met our expectations, and we are reiterating our no-moat rating. We anticipate a potential slight increase to our fair value estimate after we incorporate management's minor lift in 2019 outlook. The company raised the top end of its non-GAAP 2019 EPS guidance range by four cents, which now spans $3.38-$3.50 (versus our previous estimate of $3.40). We continue to view 2019 as a transitional year for Henry Schein, as the company works through it...
From our perspective, Henry Schein's position as a major supplier to dental practices has deteriorated over the last few years, as competition within the dental consumable segment has increased significantly. What has ensued for Schein has been inconsistent growth and pressured profits. From what we can gather, the increased competition has emanated from new online-based wholesale players that can source consumables from the cheapest suppliers nationwide. We believe this pressure will last a mat...
Henry Schein's fiscal fourth-quarter results mostly met our expectations, while the company's fiscal 2019 guidance is below our forecast. Management's fiscal 2019 adjusted EPS range of $3.38-$3.46 falls below our prediction of $3.68. We are reiterating our narrow-moat rating, but we may reduce our fair value estimate after we incorporate management's lower-than-anticipated 2019 outlook. We are not surprised by management labeling 2019 as a transitional year, as the company continues to work th...
From our perspective, Henry Schein's position as a major supplier to dental practices has deteriorated over the last few years, as competition within the dental consumable segment has increased significantly. What has ensued for Schein has been inconsistent growth and pressured profits. From what we can gather, the increased competition has emanated from new online-based wholesale players that can source consumables from the cheapest suppliers nationwide. We believe this pressure will last a mat...
Henry Schein's fiscal fourth-quarter results mostly met our expectations, while the company's fiscal 2019 guidance is below our forecast. Management's fiscal 2019 adjusted EPS range of $3.38-$3.46 falls below our prediction of $3.68. We are reiterating our narrow-moat rating, but we may reduce our fair value estimate after we incorporate management's lower-than-anticipated 2019 outlook. We are not surprised by management labeling 2019 as a transitional year, as the company continues to work th...
Henry Schein's fiscal fourth-quarter results mostly met our expectations, while the company's fiscal 2019 guidance is below our forecast. Management's fiscal 2019 adjusted EPS range of $3.38-$3.46 falls below our prediction of $3.68. We are reiterating our narrow-moat rating, but we may reduce our fair value estimate after we incorporate management's lower-than-anticipated 2019 outlook. We are not surprised by management labeling 2019 as a transitional year, as the company continues to work th...
Henry Schein's fiscal fourth-quarter results mostly met our expectations, while the company's fiscal 2019 guidance is below our forecast. Management's fiscal 2019 adjusted EPS range of $3.38-$3.46 falls below our prediction of $3.68. We are reiterating our narrow-moat rating, but we may reduce our fair value estimate after we incorporate management's lower-than-anticipated 2019 outlook. We are not surprised by management labeling 2019 as a transitional year, as the company continues to work th...
From our perspective, Henry Schein's position as a major supplier to dental practices has deteriorated over the last few years, as competition within the dental consumable segment has increased significantly. What has ensued for Schein has been inconsistent growth and pressured profits. From what we can gather, the increased competition has emanated from new online-based wholesale players that can source consumables from the cheapest suppliers nationwide. We believe this pressure will last over ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.